{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T09:24:07Z","timestamp":1768555447364,"version":"3.49.0"},"posted":{"date-parts":[[2021,10,3]]},"group-title":"Rheumatology","reference-count":39,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2021,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>In order to identify risk factors for SARS-CoV-2 infection as well as for severe\/critical COVID-19 in rheumatic and musculoskeletal diseases (RMDs) patients, we conducted a multicentre observational nationwide study of adult patients prospectively-followed in the Rheumatic Diseases Portuguese Register \u2013 Reuma.pt \u2013 during the first 6 months of the pandemic. We further evaluated the development of IgG antibodies against the receptor-binding domain (RBD) of SARS-CoV-2 in patients with RMDs. We used multivariate logistic regression to compare patients with COVID-19 (COVID-19+) with those who did not develop the disease (COVID-19-) and patients with mild\/moderate disease with those exhibiting severe\/critical COVID-19. COVID-19+ patients were asked to collect a blood sample for IgG testing \u2265 3 months after infection and results were compared with age-, sex- and sampling date-matched controls. Overall, 179 cases of COVID-19 were registered in Reuma.pt in the period of interest (median age 55 (IQR 20); 76.5% females) in a total of 6404 registered appointments. We found that patients treated with TNF inhibitors had reduced odds of infection (OR=0.16, 95%CI 0.10-0.26, p&lt;0.001), severe disease (OR 0.11, 95%CI 0.01-0.84, p=0.010) and seroconversion rates (OR 0.13, 95%CI 0.02-0.91, p=0.040). Tocilizumab was also associated with a reduced risk of COVID-19 (OR 0.15, 95%CI 0.05-0.41, p&lt;0.001). Older age, major comorbidities (diabetes, hypertension, obesity, cardiovascular disease, chronic pulmonary and kidney disease) and rituximab were associated with an increased risk of infection and worse prognosis, in line with previous reports. Importantly, most patients with inflammatory RMDs (86.2%) were able to develop a robust antibody response after SARS-CoV-2 infection, which was linked with disease severity.<\/jats:p>","DOI":"10.1101\/2021.10.01.21264428","type":"posted-content","created":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T19:35:45Z","timestamp":1633376145000},"source":"Crossref","is-referenced-by-count":0,"title":["Risk factors for infection, predictors of severe disease and antibody response to COVID-19 in patients with rheumatic diseases in Portugal \u2013 a multicentre, nationwide study"],"prefix":"10.64898","author":[{"given":"Ana Rita","family":"Cruz-Machado","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6807-559X","authenticated-orcid":false,"given":"Sofia C","family":"Barreira","sequence":"additional","affiliation":[]},{"given":"Matilde","family":"Bandeira","sequence":"additional","affiliation":[]},{"given":"Marc","family":"Veldhoen","sequence":"additional","affiliation":[]},{"given":"Andreia","family":"Gomes","sequence":"additional","affiliation":[]},{"given":"Marta","family":"Serrano","sequence":"additional","affiliation":[]},{"given":"Catarina","family":"Duarte","sequence":"additional","affiliation":[]},{"given":"Maria","family":"Rato","sequence":"additional","affiliation":[]},{"given":"Bruno Miguel","family":"Fernandes","sequence":"additional","affiliation":[]},{"given":"Salom\u00e9","family":"Garcia","sequence":"additional","affiliation":[]},{"given":"Filipe","family":"Pinheiro","sequence":"additional","affiliation":[]},{"given":"Miguel","family":"Bernardes","sequence":"additional","affiliation":[]},{"given":"Nathalie","family":"Madeira","sequence":"additional","affiliation":[]},{"given":"Cl\u00e1udia","family":"Miguel","sequence":"additional","affiliation":[]},{"given":"Rita","family":"Torres","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Bento Silva","sequence":"additional","affiliation":[]},{"given":"Jorge","family":"Pestana","sequence":"additional","affiliation":[]},{"given":"Diogo","family":"Almeida","sequence":"additional","affiliation":[]},{"given":"Carolina","family":"Mazeda","sequence":"additional","affiliation":[]},{"given":"Filipe","family":"Cunha Santos","sequence":"additional","affiliation":[]},{"given":"Patr\u00edcia","family":"Pinto","sequence":"additional","affiliation":[]},{"given":"Marlene","family":"Sousa","sequence":"additional","affiliation":[]},{"given":"Hugo","family":"Parente","sequence":"additional","affiliation":[]},{"given":"Gra\u00e7a","family":"Sequeira","sequence":"additional","affiliation":[]},{"given":"Maria Jos\u00e9","family":"Santos","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o Eurico","family":"Fonseca","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5603-9436","authenticated-orcid":false,"given":"Vasco C","family":"Rom\u00e3o","sequence":"additional","affiliation":[]}],"member":"54368","reference":[{"issue":"6","key":"2021100509150922000_2021.10.01.21264428v1.1","doi-asserted-by":"crossref","first-page":"e01218","DOI":"10.1213\/XAA.0000000000001218","article-title":"Coronavirus Disease 2019: In-Home Isolation Room Construction","volume":"14","year":"2020","journal-title":"AA Pract"},{"key":"2021100509150922000_2021.10.01.21264428v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.03.017"},{"key":"2021100509150922000_2021.10.01.21264428v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.04.021"},{"key":"2021100509150922000_2021.10.01.21264428v1.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.3002"},{"key":"2021100509150922000_2021.10.01.21264428v1.5","doi-asserted-by":"crossref","unstructured":"Strangfeld A , Sch\u00e4fer M , Gianfrancesco MA , Lawson-Tovey S , Liew JW , Ljung L , et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021 Jan 27;annrheumdis-2020-219498.","DOI":"10.1136\/annrheumdis-2021-220134"},{"issue":"12","key":"2021100509150922000_2021.10.01.21264428v1.6","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1002\/art.41456","article-title":"COVID-19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease-Modifying Antirheumatic Drugs on Clinical Outcomes","volume":"72","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2021100509150922000_2021.10.01.21264428v1.7","doi-asserted-by":"crossref","unstructured":"Esperan\u00e7a-Martins M , Gon\u00e7alves L , Soares-Pinho I , Gomes A , Serrano M , Blankenhaus B , et al. Humoral Immune Response of SARS-CoV-2\u2013Infected Patients with Cancer: Influencing Factors and Mechanisms. The Oncologist [Internet]. 2021 May 20 [cited 2021 Jul 24];n\/a(n\/a). Available from: https:\/\/doi.org\/10.1002\/onco.13828","DOI":"10.1002\/onco.13828"},{"key":"2021100509150922000_2021.10.01.21264428v1.8","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202048970"},{"key":"2021100509150922000_2021.10.01.21264428v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.05.001"},{"key":"2021100509150922000_2021.10.01.21264428v1.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217424"},{"issue":"9","key":"2021100509150922000_2021.10.01.21264428v1.11","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00296-020-04629-x","article-title":"Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes","volume":"40","year":"2020","journal-title":"Rheumatol Int"},{"key":"2021100509150922000_2021.10.01.21264428v1.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-00562-2"},{"key":"2021100509150922000_2021.10.01.21264428v1.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217681"},{"key":"2021100509150922000_2021.10.01.21264428v1.14","doi-asserted-by":"crossref","first-page":"102468","DOI":"10.1016\/j.jaut.2020.102468","article-title":"The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19","volume":"111","year":"2020","journal-title":"J Autoimmun"},{"key":"2021100509150922000_2021.10.01.21264428v1.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102442"},{"issue":"1","key":"2021100509150922000_2021.10.01.21264428v1.16","first-page":"45","article-title":"Rheumatic Diseases Portuguese Register Board Coordination, Portuguese Society of Rheumatology. Reuma.pt - the rheumatic diseases portuguese register","volume":"36","year":"2011","journal-title":"Acta Reumatol Port"},{"key":"2021100509150922000_2021.10.01.21264428v1.17","unstructured":"World Health Organization (WHO). Global surveillance for COVID-19 caused by human infection with COVID-19 virus: interim guidance 2020. [Internet]. Available from: www.who.int\/emergencies\/diseases\/novelcoronavirus-%0A2019\/technical-guidance\/surveillance-and-case-definitions."},{"key":"2021100509150922000_2021.10.01.21264428v1.18","doi-asserted-by":"crossref","unstructured":"World Health Organization (WHO). Clinical Management of Severe Acute Respiratory Infection (SARI) When COVID-19 Disease Is Suspected: Interim Guidance. 2020.","DOI":"10.15557\/PiMR.2020.0003"},{"key":"2021100509150922000_2021.10.01.21264428v1.19","doi-asserted-by":"crossref","unstructured":"Centers for disease control and prevention. CDC Interim Guidelines for COVID-19 Antibody Testing. [Internet]. Available from: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/lab\/resources\/antibody-tests-guidelines.html#","DOI":"10.46234\/ccdcw2020.085"},{"issue":"7821","key":"2021100509150922000_2021.10.01.21264428v1.20","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","article-title":"Convergent antibody responses to SARS-CoV-2 in convalescent individuals","volume":"584","year":"2020","journal-title":"Nature"},{"issue":"3","key":"2021100509150922000_2021.10.01.21264428v1.21","doi-asserted-by":"crossref","first-page":"100040","DOI":"10.1016\/j.xcrm.2020.100040","article-title":"Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients","volume":"1","year":"2020","journal-title":"Cell Rep Med"},{"key":"2021100509150922000_2021.10.01.21264428v1.22","doi-asserted-by":"crossref","unstructured":"Stadlbauer D , Amanat F , Chromikova V , Jiang K , Strohmeier S , Arunkumar GA , et al. SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup. Curr Protoc Microbiol [Internet]. 2020 Jun [cited 2021 Jul 4];57(1). Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cpmc.100","DOI":"10.1002\/cpmc.100"},{"key":"2021100509150922000_2021.10.01.21264428v1.23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-039849"},{"key":"2021100509150922000_2021.10.01.21264428v1.24","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3389\/fpubh.2020.00418","article-title":"Racial and Gender-Based Differences in COVID-19","volume":"8","year":"2020","journal-title":"Front Public Health"},{"issue":"7","key":"2021100509150922000_2021.10.01.21264428v1.25","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1007\/s10067-020-05189-y","article-title":"COVID-19, chronic inflammatory rheumatic disease and anti-rheumatic treatments","volume":"39","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2021100509150922000_2021.10.01.21264428v1.26","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001439"},{"key":"2021100509150922000_2021.10.01.21264428v1.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17703-6"},{"key":"2021100509150922000_2021.10.01.21264428v1.28","unstructured":"Our world in data [Internet]. Available from: https:\/\/ourworldindata.org\/grapher\/weekly-hospital-admissions-covid"},{"issue":"6","key":"2021100509150922000_2021.10.01.21264428v1.29","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1016\/S2665-9913(21)00059-X","article-title":"COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study","volume":"3","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"2021100509150922000_2021.10.01.21264428v1.30","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1016\/S2665-9913(21)00077-1","article-title":"Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic","volume":"3","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2021100509150922000_2021.10.01.21264428v1.31","unstructured":"FAI2R \/SFR\/SNFMI\/SOFREMIP\/CRI\/IMIDIATE consortium and contributors. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis. 2020 Dec 2;annrheumdis-2020-218310."},{"key":"2021100509150922000_2021.10.01.21264428v1.32","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001464"},{"key":"2021100509150922000_2021.10.01.21264428v1.33","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219808"},{"key":"2021100509150922000_2021.10.01.21264428v1.34","doi-asserted-by":"crossref","unstructured":"Saxena A , Guttmann A , Masson M , Kim MY , Haberman RH , Castillo R , et al. Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort. Lancet Rheumatol. 2021 May;S2665991321001144.","DOI":"10.1136\/lupus-2021-lupus21century.73"},{"issue":"5","key":"2021100509150922000_2021.10.01.21264428v1.35","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1080\/21645515.2019.1574151","article-title":"High dose hepatitis B vaccine is not effective in patients using immunomodulatory drugs: a pilot study","volume":"15","year":"2019","journal-title":"Hum Vaccines Immunother"},{"key":"2021100509150922000_2021.10.01.21264428v1.36","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.3966"},{"issue":"12","key":"2021100509150922000_2021.10.01.21264428v1.37","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1038\/s41564-020-00813-8","article-title":"Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans","volume":"5","year":"2020","journal-title":"Nat Microbiol"},{"key":"2021100509150922000_2021.10.01.21264428v1.38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2025179pmid:32706954"},{"key":"2021100509150922000_2021.10.01.21264428v1.39","doi-asserted-by":"crossref","unstructured":"Gallais F , Gantner P , Bruel T , Velay A , Planas D , Wendling M-J , et al. Anti-SARS-CoV-2 Antibodies Persist for up to 13 Months and Reduce Risk of Reinfection. medRxiv. 2021;","DOI":"10.1101\/2021.05.07.21256823"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2021.10.01.21264428","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T14:26:36Z","timestamp":1768487196000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2021.10.01.21264428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,3]]},"references-count":39,"URL":"https:\/\/doi.org\/10.1101\/2021.10.01.21264428","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.3389\/fmed.2022.901817","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2021,10,3]]},"subtype":"preprint"}}